Company

Merck & Co.

Rahway, New Jersey pharmaceutical company; discovered belzutifan (Welireg) and, with Eisai's lenvatinib (Lenvima), now markets the combination for advanced kidney cancer after immunotherapy.

merck.com

5 stories

Regulatory News has published 5 stories about Merck & Co. between 23 September 2026 and 4 October 2026, each sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 4 October 2026.

This page is generated from Regulatory News’ editorial coverage of Merck & Co.. It is not an advertisement.

Products in our coverage

Our coverage

5 stories, newest first.

A scientist examines a sample under a microscope in a bright laboratory

For Physicians Daiichi Sankyo, Merck Pull Lung Cancer ADC Filing Oct 4, 20269 min read Read the story

A senior physician in a white coat reads clinical notes in a hospital corridor

For Physicians FDA Approves Belzutifan-Lenvatinib Combo for Kidney Cancer Sep 28, 20267 min read Read the story

A team reviews charted figures and percentages on a whiteboard during an office planning session

For Physicians FDA Label Now Backs Early Winrevair Use in PAH Sep 27, 20267 min read Read the story

Two physicians in white coats review a chart on a clipboard together in a hospital exam room

Drugs & Biologics FDA Clears Welireg-Lenvima Combo for Kidney Cancer Sep 26, 20266 min read Read the story

Two researchers in lab coats and nitrile gloves examine flasks of colored liquid during a laboratory review

Drugs & Biologics FDA Expands WINREVAIR Label With HYPERION Data Sep 23, 20266 min read Read the story

All companies